Saturna Capital analyst Paul Meeks provides his investment strategy for the remainder of the year, including the plays in mobile, cloud, social and big data.
William Muggia, Westfield Capital; Thomas Atteberry, FPA partner, and David Darst, Morgan Stanley Wealth Management, provide their second half plays on stocks, bonds and interest rates.
Some of the names on the move ahead of the open.
Gold is "trading very emotionally," says Adam Grimes, Waverly Advisors, discussing why he believes the precious metal is losing its luster and is now trading more like "a risk asset."
Mark Luschini, Janney Montgomery Scott, and David Darst, Morgan Stanley Wealth Management, provide their investment strategies for the next six months, as the markets face a slew of challenges, including a possible pullback in the Fed's asset-buying program.
Ashwani Kaul, Kaul Advisory Group, provides his projections on which sectors will likely prove to be the real earnings bright spots in the second quarter.
Ed Maguire, CLSA analyst, discusses how the change in management at the tech giant is likely part of its restructuring plans to transition into a service company and grow its cloud business.
CNBC's Ross Westgate reports on all the market moving events from Europe, as stock-specific news weighed down individual indexes.
CNBC's Ross Westgate tells you what the markets will be watching as we approach the start of trading in the U.S.
Medivation has already made a big move, but the bulls are looking for more.
Gregg Lemkau, co-head of global mergers and acquisitions at Goldman Sachs, says the low level of M&A activity is "frustrating" as all the usual drivers are there and explains what's holding investors back.
Are the markets in a super-bull cycle? Liz Ann Sonders, Charles Schwab; Jeff Kilburg, KKM Financial; Jeremy Siegel, Wharton Finance professor; and Zane Brown, Lord Abbett, share their opinions.
Mad Money host Jim Cramer shares his final thoughts of the day.
Following is Cramer's research or homework on stocks recently called to his attention by Mad Money viewers.
Catching up on biotech stocks Trius Therapeutics, Array Biopharma and Cytokinetics, with Mad Money host Jim Cramer.
You say the name of a stock, and Mad Money's Jim Cramer tells you whether to buy or sell.
The trick to successful investing is knowing when to take profits and walk away. In this case, Cramer says it’s time.
Onyx Pharmaceuticals is seeking out more competitive offers beyond Amgen's $10 billion takeover bid. "Mad Money" host Jim Cramer says there are better opportunities in the biotech space right now.
The Street often rewards growth potential. But this is ridiculous, isn’t it?
Casual restaurant Noodles & Co. currently operates 343 restaurants, 52 of which are franchised. Mad Money host Jim Cramer says the company is very well run, but that investors should wait for a market pullback before buying.